Cargando…
High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers
Autores principales: | Palich, R., Veyri, M., Vozy, A., Marot, S., Gligorov, J., Benderra, M.-A., Maingon, P., Morand-Joubert, L., Adjoutah, Z., Marcelin, A.-G., Spano, J.-P., Barrière, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217700/ https://www.ncbi.nlm.nih.gov/pubmed/34171494 http://dx.doi.org/10.1016/j.annonc.2021.06.018 |
Ejemplares similares
-
Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
por: Palich, R., et al.
Publicado: (2021) -
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
por: Alqassieh, Rami, et al.
Publicado: (2021) -
Sub-cutaneous Pfizer/BioNTech COVID-19 vaccine administration results in seroconversion among young adults
por: Friedensohn, Limor, et al.
Publicado: (2021) -
Myocarditis with Pfizer-BioNTech's COVID-19 vaccine in Israel
Publicado: (2021) -
Thrombocytopenia with Pfizer-BioNTech or Moderna COVID-19 vaccines
Publicado: (2021)